Galmed Pharmaceuticals (GLMD) Net Income (QoQ) (2013 - 2025)
Galmed Pharmaceuticals (GLMD) Net Income (QoQ) (2013 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Galmed Pharmaceuticals | 2.31 Mn | -9.57 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 24.17% |
| Jun 30, 2025 | -126.00% |
| Sep 30, 2024 | 47.83% |
| Jun 30, 2024 | -387.76% |
| Sep 30, 2023 | -71.96% |
| Jun 30, 2023 | 387.05% |
| Mar 31, 2023 | -110.76% |
| Dec 31, 2022 | 167.73% |
| Sep 30, 2022 | -362.07% |
| Jun 30, 2022 | 3,114.43% |
| Mar 31, 2022 | 100.52% |
| Dec 31, 2021 | -235.84% |
| Sep 30, 2021 | 604.00% |
| Jun 30, 2021 | 5.72% |
| Mar 31, 2021 | -186.65% |
| Dec 31, 2020 | -65.84% |
| Sep 30, 2020 | 644.39% |
| Jun 30, 2020 | 8.86% |
| Mar 31, 2020 | -118.58% |
| Dec 31, 2019 | 264.53% |